Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

By J. Wolchok, V. Chiarion-Sileni, R. Gonzalez, P. Rutkowski, J. Grob, L. Cowey, C. Lao, J. Wagstaff, D. Schadendorf, P. Ferrucci and 23 more. New England Journal of Medicine, 2017

3,400 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/23dbeed54cde655fb6a12697b02c9ff303515da7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Anand Rotte
2. Nicholas McGranahan
3. Charles Swanton
4. J. Wolchok

In Oncology

1. Anand Rotte
2. J. Wolchok
3. Nicholas McGranahan
4. F. Hodi
5. M. Hellmann
6. M. Callahan
7. Georgina V. Long
8. Charles Swanton

Citations in the corpus

• Genomic features of response to combination immunotherapy in patients with advanced non-small cell lung cancer (2018, background): “, 2015) and clinical reports (Gao et al., 2016; George et al., 2017; Zaretsky et al., 2016) have described associations between individual altered genes and response or resistance to immune checkpoint blockade (Table S4).”
• Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma (2021, methodology): “OS results at 6.5 years in patient subgroups on the basis of tumor programmed cell death ligand 1 expression level were consistent with those reported previously (Data Supplement).5-7 ORRs at 6.5 years remained unchanged from the previous analysis at 5 years,7 with rates of 58%, 45%, and 19% with th”
• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “73 favouring the combination in patient with LDH >2 x upper limit of normal (ULN) [63, 67], though evidence for the latter is weaker [III, B].”